@dengyuemedicine.bsky.social🚨 China's NMPA just approved two new monoclonal antibodies — Retavibart & Clulevibart — to prevent RSV-related lower respiratory infections in newborns & infants.
A major step forward in protecting the most vulnerable patients this flu season. 🍼